System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions

• US 20120238836A1
• Filed: 03/17/2011
• Published: 09/20/2012
• Est. Priority Date: 03/16/2011
• Status: Abandoned Application

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC A Limited Liability Corporation of The State of Delaware
• Inventors: Hyde, Roderick A., Wolda, Sharon L., Wood, Lowell L. Jr.
• Application Number:
  US13/065,328
• Publication Number:
  US 20120238836A1
• Time in Patent Office: Days
• US Class Current: 600/309
• CPC Class Codes: A61B 5/14507 specially adapted for measuring characteristics of body fluids other than blood devices for taking samples of body liquids A61B10/0045
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61B 5/4058 for evaluating the central nervous system A61B5/4806, A61B5/4821 take precedence
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: A61B 5/6868 Brain
• CPC Class Codes: A61M 27/006 Cerebrospinal drainage; Accessories therefor, e.g. valves

Abstract

Systems, devices, methods, and compositions are described for providing real-time monitoring of cerebrospinal fluid for markers of progressive conditions.

Claims

1-213. -213. (canceled)

214. A method for predicting an onset of a depressive disorder, comprising:

transcutaneously communicating a suicidal tendency status in response to an in vivo comparison of cerebrospinal fluid neuropeptide compositional information of a cerebrospinal fluid received within the one or more fluid-flow passageways of an indwelling implant to reference mental disorder filtering information.

215. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes transcutaneously communicating a suicidal tendency status in response to an in vivo comparison of cerebrospinal fluid neuropeptide compositional information of a cerebrospinal fluid received within the one or more fluid-flow passageways of an indwelling implant to user-specific reference mental disorder filtering information.

217. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes transmitting a cerebrospinal fluid Orexin-A level status.

218. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes transmitting a cerebrospinal fluid somatostatin level.

219. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes transmitting a cerebrospinal fluid delta-sleep-inducing peptide DSIP-LI level.

224. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes transmitting predictive model information generated based on a time progression of detected changes in concentration levels of one or more cerebrospinal fluid components associated with an onset of a depressive disorder.

225. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes transmitting a relative level of at least two of a cerebrospinal fluid Orexin-A level, a cerebrospinal fluid somatostatin level, a cerebrospinal fluid delta-sleep-inducing peptide DSIP-LI level, or a cerebrospinal fluid corticotrophin releasing factor level.

226. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes wirelessly communicating the suicidal tendency status to a remote device.

230. The method of predicting the onset of the depressive disorder of claim 214, wherein transcutaneously communicating the suicidal tendency status includes transcutaneously transmitting the suicidal tendency in response to a received request.

231. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

storing comparison information associated with the in vivo comparison of the cerebrospinal fluid neuropeptide compositional information of the cerebrospinal fluid received within the one or more fluid-flow passageways of the indwelling implant to the reference mental disorder filtering information based on a target criterion.

232. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

storing time series comparison information associated with the in vivo comparison of the cerebrospinal fluid neuropeptide compositional information of the cerebrospinal fluid received within the one or more fluid-flow passageways of the indwelling implant to the reference mental disorder filtering information in one or more data structures of the indwelling implant.

233. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

storing paired and unpaired comparison data associated with the in vivo comparison of the cerebrospinal fluid neuropeptide compositional information of the cerebrospinal fluid received within the one or more fluid-flow passageways of the indwelling implant to the reference mental disorder filtering information in one or more data structures of the indwelling implant.

234. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

storing the cerebrospinal fluid neuropeptide compositional information of the cerebrospinal fluid received within the one or more fluid-flow passageways of the indwelling in one or more data structures of the indwelling implant.

235. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

generating one or more concurrent or sequential in vivo comparisons of the cerebrospinal fluid neuropeptide compositional information of the cerebrospinal fluid received within the one or more fluid-flow passageways of the indwelling implant to the reference mental disorder filtering information.

236. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

detecting cerebrospinal fluid neuropeptide compositional information of the cerebrospinal fluid received within the one or more fluid-flow passageways of the indwelling implant at a plurality of sequential time points; and

concurrently or sequentially generating in vivo comparisons of the detected cerebrospinal fluid neuropeptide compositional information to the reference mental disorder filtering information

prior to transcutaneously communicating the suicidal tendency status.

237. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

generating a predictive model based on time series information derived from comparing cerebrospinal fluid neuropeptide compositional information of a cerebrospinal fluid received within the one or more fluid-flow passageways of an indwelling implant to reference mental disorder filtering information.

238. The method of predicting the onset of the depressive disorder of claim 237, further comprising:

transcutaneously communicating predictive model information associated with the generated predictive model.

239. The method of predicting the onset of the depressive disorder of claim 214, further comprising:

generating a predictive model based on a time progression of one or more changes in concentration levels of one or more cerebrospinal fluid components associated with an onset of a depressive disorder.

240. The method of predicting the onset of the depressive disorder of claim 239, further comprising:

transcutaneously communicating predictive model information associated with the generated predictive model.

216. (canceled)

220-223. -223. (canceled)

227-229. -229. (canceled)

241. A method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies, comprising:

detecting in vivo cerebrospinal fluid compositional information of a biological subject indicative of a change to a cerebrospinal fluid serotonin metabolite level via one or more indwelling implants at a plurality of sequential times;

in situ, real-time, comparing of detected in vivo cerebrospinal fluid compositional information to user-specific compositional model information; and

generating a suicidal tendency status.

246. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, wherein detecting the in vivo cerebrospinal fluid compositional information of the biological subject includes measuring compositional information associated with a monoamine metabolite level.

247. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, wherein detecting the in vivo cerebrospinal fluid compositional information of the biological subject includes measuring compositional information associated with a 5-hydroxyindolacetic acid level.

248. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, wherein detecting the in vivo cerebrospinal fluid compositional information of the biological subject includes detecting the in vivo cerebrospinal fluid compositional information of the biological subject at a first time interval, and wherein in situ, real-time, comparing of the detected in vivo cerebrospinal fluid compositional information to user-specific compositional model information includes computing the comparison of the detected in vivo cerebrospinal fluid compositional information of the biological subject at for the first time interval to the user-specific compositional model information prior to detecting the in vivo cerebrospinal fluid compositional information of the biological subject at a second time interval.

250. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, wherein in situ, real-time, comparing of the detected in vivo cerebrospinal fluid compositional information to user-specific compositional model information includes computing a difference between a detected spectral intensity and a respective user-specific reference spectral intensity.

251. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, wherein in situ, real-time, comparing of the detected in vivo cerebrospinal fluid compositional information to user-specific compositional model information includes computing a difference between a detected compositional intensity and a respective user-specific compositional intensity.

255. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, further comprising:

generating predictive model information based on the detected in vivo cerebrospinal fluid compositional information of the biological subject; and

updating the user-specific compositional model information based on the generated predict model information prior to in situ, real-time, comparing.

256. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, further comprising:

generating predictive model information based on the detected first time series of in vivo cerebrospinal fluid compositional information of the biological subject; and

performing an in situ real-time comparison of the predictive model information to the user-specific compositional model information.

257. The method for monitoring cerebrospinal fluid biomarkers indicative of suicidal tendencies of claim 241, further comprising:

generating a suicidal tendency status in response to in situ, real-time, comparing of the predictive model information to the user-specific compositional model information.

242-245. -245. (canceled)

249. (canceled)

252-254. -254. (canceled)

258. A method for monitoring a pathological condition associated with a suicidal tendency, comprising:

real-time detecting, via an implanted shunt, one or more compositional components associated with at least one cerebrospinal fluid cholecystokinin peptide; and

generating at least one of an anxiety report, a depression status report, or a suicidal tendency report in response to spectral information associated with the real-time detected one or more compositional components associated with the at least one cerebrospinal fluid cholecystokinin peptide.

259. The method for monitoring a pathological condition associated with a suicidal tendency of claim 258, wherein generating the at least one of the anxiety report, the depression status report, or the suicidal tendency report includes generating at least one of a visual, an audio, a haptic, or a tactile representation of at least one spectral component associated with the cerebrospinal fluid cholecystokinin peptide when a cholecystokinin peptide level satisfies a target criterion.

260-262. -262. (canceled)

263-391. -391. (canceled)